Cargando…

Layer‐by‐layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum‐based drug resistance therapy in ovarian cancer

Advanced staged high‐grade serous ovarian cancer (HGSOC) is the leading cause of gynecological cancer death in the developed world, with 5‐year survival rates of only 25–30% due to late‐stage diagnosis and the shortcomings of platinum‐based therapies. A Phase I clinical trial of a combination of fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mensah, Lawrence B., Morton, Stephen W., Li, Jiahe, Xiao, Haihua, Quadir, Mohiuddin A., Elias, Kevin M., Penn, Emily, Richson, Aysen K., Ghoroghchian, Paiman Peter, Liu, Joyce, Hammond, Paula T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2019
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6584097/ https://www.ncbi.nlm.nih.gov/pubmed/31249881 http://dx.doi.org/10.1002/btm2.10131

Ejemplares similares

Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
por: McMullen, Michelle, et al.
Publicado: (2020)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
por: Kim, Hyoung, et al.
Publicado: (2020)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Electrochemical growth mechanism of nanoporous platinum layers
por: Stanca, Sarmiza-Elena, et al.
Publicado: (2021)

Platinum Dissolution in Realistic Fuel Cell Catalyst Layers
por: Ehelebe, Konrad, et al.
Publicado: (2021)

The role of the double layer for the pseudocapacitance of the hydrogen adsorption on platinum
por: Schalenbach, Maximilian, et al.
Publicado: (2022)

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
por: Agarwal, Amit, et al.
Publicado: (2021)

Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Sun, Li, et al.
Publicado: (2022)

Layer‐by‐layer interleukin‐12 nanoparticles drive a safe and effective response in ovarian tumors
por: Barberio, Antonio E., et al.
Publicado: (2022)

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
por: Qi, Ruogu, et al.
Publicado: (2017)

Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?
por: Batista, Thales Paulo, et al.
Publicado: (2020)

Ovarian cancer recurrence: “is the definition of platinum resistance modified by PARP inhibitors and other intervening treatments?”
por: Pejovic, Tanja, et al.
Publicado: (2022)

Retracted: Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Platinum nanosheets synthesized via topotactic reduction of single-layer platinum oxide nanosheets for electrocatalysis
por: Takimoto, Daisuke, et al.
Publicado: (2023)

Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
por: Qi, Ruogu, et al.
Publicado: (2018)

Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer
por: Qi, Ruogu, et al.
Publicado: (2020)

Synergistic combination therapy delivered via layer‐by‐layer nanoparticles induces solid tumor regression of ovarian cancer
por: Kong, Stephanie, et al.
Publicado: (2022)

Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer
por: Zhang, Rongrong, et al.
Publicado: (2017)

Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-by-Layer (LbL) Nanoparticles
por: Dreaden, Erik C., et al.
Publicado: (2014)

Layer-by-Layer Assembled Antisense DNA Microsponge Particles for Efficient Delivery of Cancer Therapeutics
por: Roh, Young Hoon, et al.
Publicado: (2014)

Combination Therapy of Lung Cancer Using Layer-by-Layer Cisplatin Prodrug and Curcumin Co-Encapsulated Nanomedicine
por: Hong, Yuan, et al.
Publicado: (2020)

Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer
por: Walsh, Christine S., et al.
Publicado: (2021)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Bartoletti, Michele, et al.
Publicado: (2020)

Nanoengineered Gallium Ion Incorporated Formulation for Safe and Efficient Reversal of PARP Inhibition and Platinum Resistance in Ovarian Cancer
por: Li, Yangyang, et al.
Publicado: (2023)

New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors
por: Folk, Watson P., et al.
Publicado: (2021)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
por: van der Burg, M E L, et al.
Publicado: (2002)

Platinum-bearing chromite layers are caused by pressure reduction during magma ascent
por: Latypov, Rais, et al.
Publicado: (2018)

Electrical Properties of Ultrathin Platinum Films by Plasma-Enhanced Atomic Layer Deposition
por: Kim, Hyo Jin K., et al.
Publicado: (2019)

Study on Platinum Coating Depth in Focused Ion Beam Diamond Cutting Tool Milling and Methods for Removing Platinum Layer
por: Choi, Woong Kirl, et al.
Publicado: (2015)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model
por: Modok, S, et al.
Publicado: (2007)

Extreme Gradient Boosting to Predict Atomic Layer Deposition for Platinum Nano-Film Coating
por: Yoon, Sung-Ho, et al.
Publicado: (2023)

PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)

Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy
por: Yusoh, Nur Aininie, et al.
Publicado: (2020)

Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Xu, Yangchun, et al.
Publicado: (2021)

Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
por: Wang, Hongmei, et al.
Publicado: (2021)

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
por: Sheng, W.J., et al.
Publicado: (2013)

Understanding and Controlling the Aggregative Growth of Platinum Nanoparticles in Atomic Layer Deposition: An Avenue to Size Selection
por: Grillo, Fabio, et al.
Publicado: (2017)

SURG-03. LAYER-BY-LAYER CORE-SHELL NANOPARTICLES FOR THE DELIVERY OF HDAC INHIBITORS TO THE CENTRAL NERVOUS SYSTEM
por: Marand, Michael H, et al.
Publicado: (2023)

Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13(*) cells
por: Zhang, Jingjing, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_57uvig58epfv5ck3gp5duk9b79